Lantheus Inc. (LNTH)
NASDAQ: LNTH
· Real-Time Price · USD
79.23
0.24 (0.30%)
At close: Jun 20, 2025, 3:59 PM
79.00
-0.29%
Pre-market: Jun 23, 2025, 09:01 AM EDT
Lantheus Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|
| DEFINITY Revenue | 317.79M | 279.77M | 244.99M | 232.76M | 183.07M | 157.27M | 131.61M | 72.56M |
| DEFINITY Revenue Growth | +13.59% | +14.19% | +5.26% | +27.14% | +16.41% | +19.49% | +81.38% | n/a |
| License and Royalty Revenues Revenue | 9.13M | 33.36M | 48.02M | 24.85M | 98.86M | 104.64M | 99.22M | n/a |
| License and Royalty Revenues Revenue Growth | -72.64% | -30.53% | +93.24% | -74.86% | -5.53% | +5.47% | n/a | n/a |
| Other Precision Diagnostics Revenue | 24.23M | 22.98M | 22.82M | 26.97M | n/a | n/a | n/a | n/a |
| Other Precision Diagnostics Revenue Growth | +5.44% | +0.68% | -15.38% | n/a | n/a | n/a | n/a | n/a |
| Other Radiopharmaceutical Oncology Revenue | 384K | 3.13M | 4.1M | 5.47M | n/a | n/a | n/a | n/a |
| Other Radiopharmaceutical Oncology Revenue Growth | -87.73% | -23.70% | -25.05% | n/a | n/a | n/a | n/a | n/a |
| PYLARIFY Revenue | 1.06B | 851.3M | 527.4M | 43.41M | n/a | n/a | n/a | n/a |
| PYLARIFY Revenue Growth | +24.26% | +61.41% | +1114.83% | n/a | n/a | n/a | n/a | n/a |
| Product Revenue | 1.52B | 1.26B | 531.51M | 48.89M | n/a | n/a | n/a | n/a |
| Product Revenue Growth | +20.72% | +137.64% | +987.22% | n/a | n/a | n/a | n/a | n/a |
| Radiopharmaceutical Oncology Revenue | 1.06B | 854.43M | 46.87M | 25.3M | n/a | n/a | n/a | n/a |
| Radiopharmaceutical Oncology Revenue Growth | +23.85% | +1722.91% | +85.29% | n/a | n/a | n/a | n/a | n/a |
| Strategic Partnerships And Other Revenue | 38.18M | 51.88M | 88.86M | 91.29M | n/a | n/a | n/a | n/a |
| Strategic Partnerships And Other Revenue Growth | -26.40% | -41.62% | -2.66% | n/a | n/a | n/a | n/a | n/a |
| Techne Lite Revenue | 95.49M | 87.37M | 356.68M | 351.02M | n/a | n/a | n/a | n/a |
| Techne Lite Revenue Growth | +9.29% | -75.50% | +1.61% | n/a | n/a | n/a | n/a | n/a |
| Total Precision Diagnostics Revenue | 437.51M | 390.12M | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Precision Diagnostics Revenue Growth | +12.15% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|
| Us Segment Revenue | 294.8M | 72.53M |
| Us Segment Revenue Growth | +306.42% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 99.32M | 101.41M | 84.23M | 92.54M | 93.44M | 75.56M | 73.14M | 62.61M | 55.89M | 66.62M | 49.17M | 60.09M | 57.94M | 81.95M | 45.74M | 60.81M | 30.31M | 26.54M | 29.83M | 26.98M | 26.83M | 27.69M | 28.21M | 24.24M | 22.99M | 22.35M | 24.09M | 23.7M | 23.18M | 24.72M | 22.15M | 22.81M | 22.48M | 18.68M | 18.8M | 19.08M | 18.82M | 17.93M | 17.84M | 24.67M | 18.2M |
| Selling, General, and Administrative Revenue Growth | -2.06% | +20.39% | -8.98% | -0.96% | +23.67% | +3.31% | +16.82% | +12.02% | -16.11% | +35.48% | -18.17% | +3.71% | -29.30% | +79.15% | -24.77% | +100.61% | +14.20% | -11.01% | +10.57% | +0.54% | -3.12% | -1.84% | +16.38% | +5.46% | +2.84% | -7.21% | +1.61% | +2.25% | -6.20% | +11.58% | -2.87% | +1.43% | +20.39% | -0.64% | -1.49% | +1.39% | +4.98% | +0.49% | -27.70% | +35.60% | n/a |
| Research and Development Revenue | 36.31M | 35.33M | 24.15M | 60.6M | 48.02M | 16.82M | 14.45M | 15.9M | 30.53M | 272.23M | 12.52M | 14.73M | 12.2M | 11.29M | 11.25M | 12.06M | 10.36M | 12.64M | 11.68M | 4.42M | 4.05M | 4.43M | 4.86M | 5.79M | 4.93M | 4.55M | 4.32M | 4.21M | 3.99M | 3.98M | 3.55M | 5.24M | 5.35M | 3.71M | 2.85M | 2.61M | 3.04M | 3.07M | 2.46M | 2.64M | 6.2M |
| Research and Development Revenue Growth | +2.80% | +46.29% | -60.15% | +26.19% | +185.45% | +16.43% | -9.13% | -47.92% | -88.78% | +2074.85% | -15.05% | +20.75% | +8.06% | +0.36% | -6.71% | +16.42% | -18.03% | +8.17% | +164.46% | +9.14% | -8.71% | -8.77% | -16.13% | +17.57% | +8.31% | +5.44% | +2.40% | +5.67% | +0.33% | +11.87% | -32.23% | -2.00% | +44.23% | +30.22% | +9.24% | -14.10% | -0.98% | +24.74% | -6.82% | -57.42% | n/a |
| Sales and Marketing Revenue | 42.5M | 43.64M | 43.72M | 45.03M | 45.55M | 35.26M | 37.4M | 36.46M | 32.62M | 26.98M | 25.41M | 27.49M | 20.35M | 19.42M | 17.2M | 17.63M | 14.17M | 12.86M | 11.61M | 6.3M | 10.13M | 10.39M | 10.15M | 10.95M | 10.4M | 9.91M | 10.48M | 12.13M | 10.64M | 10.42M | 10.07M | 11.6M | 10.21M | 8.69M | 8.71M | 9.84M | 9.31M | 7.81M | 8.63M | 9.23M | 9.07M |
| Sales and Marketing Revenue Growth | -2.61% | -0.18% | -2.92% | -1.12% | +29.16% | -5.71% | +2.59% | +11.77% | +20.88% | +6.17% | -7.56% | +35.07% | +4.79% | +12.96% | -2.47% | +24.40% | +10.24% | +10.75% | +84.12% | -37.76% | -2.52% | +2.37% | -7.28% | +5.30% | +4.90% | -5.41% | -13.62% | +14.00% | +2.08% | +3.45% | -13.17% | +13.60% | +17.59% | -0.23% | -11.55% | +5.76% | +19.23% | -9.58% | -6.46% | +1.73% | n/a |